Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | SCN1A | P35498 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10926726 | 0.98 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2TSHRNPSR1KEAP1 | |
| SCHEMBL24389176 | 0.98 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2TSHRNPSR1KEAP1 | |
| SCHEMBL85427 | 0.94 | HRH3 (0.56) | ALDH1A1SMN1; SMN2TSHRNPSR1KEAP1 | |
| SCHEMBL22876707 | 0.89 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2TSHRNPSR1KEAP1 | |
| SCHEMBL20332380 | 0.86 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2TSHRNPSR1KEAP1 | |
| SCHEMBL21148408 | 0.86 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2TSHRNPSR1KEAP1 | |
| SCHEMBL13845059 | 0.86 | HRH3 (0.50) | ALDH1A1SMN1; SMN2TSHRNPSR1KEAP1 | |
| SCHEMBL20332795 | 0.86 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2TSHRNPSR1KEAP1 | |
| SCHEMBL20332826 | 0.86 | TDP1 (0.47) | ALDH1A1SMN1; SMN2TSHRNPSR1KEAP1 | |
| SCHEMBL501602 | 0.86 | TSHR (0.53) | ALDH1A1SMN1; SMN2TSHRNPSR1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4272825-A2 | MTORC MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230331737-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11702429-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230013344-A1 | MTORC MODULATORS AND USES THEREOF | EVOTEC (FRANCE) SAS (FR) | 2023-01-19 | — | — | US | disclosed |
| US-20220267352-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2022-08-25 | — | — | US | disclosed |
| US-11230557-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11021492-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210008041-A1 | MTORC MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2021-01-14 | — | — | US | disclosed |
| US-20210002300-A1 | MTORC MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2021-01-07 | — | — | US | disclosed |
| WO-2020154447-A1 | MTORC MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| US-20070027318-A1 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-02-01 | — | — | US | disclosed |
| US-20070027318-A1 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-02-01 | — | — | US | disclosed |
| US-7169789-B2 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-01-30 | — | — | US | disclosed |
| US-7169789-B2 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-01-30 | — | — | US | disclosed |
| EP-1054865-A1 | FARNESYL TRANSFERASE INHIBITORS | AstraZeneca UK Limited (GB) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999041235-A1 | FARNESYL TRANSFERASE INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 1999-08-19 | — | — | WO | disclosed |
| EP-0154669-A1 | Catalyst for urethane foam blown with carboxylic acids | ABBOTT LABORATORIES (US) | 1985-09-18 | — | — | EP | disclosed |
| EP-0144573-A2 | Catalyst system for the production of polyurethanes | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1985-06-19 | — | — | EP | disclosed |
| US-4500654-A | N-SUBSTITUTED ALKOXYALKYL PIPERAZINE | ABBOTT LABORATORIES (US) | 1985-02-19 | — | — | US | disclosed |
| US-4473666-A | A DIALKYLCYCLOHEXYLAMINE AND AN N-SUBSTITUTED ALKOXYALKYL PIPERAZINE | ABBOTT LABORATORIES (US) | 1984-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267352-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | RICTOR, MTOR, RPTOR | ALDH1A1 4627/4885SMN1; SMN2 2228/4885TSHR 3810/4885 |
| US-11702429-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | ALDH1A1 4766/4885SMN1; SMN2 2851/4885TSHR 3270/4885 |
| US-20210008041-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | ALDH1A1 4766/4885SMN1; SMN2 2851/4885TSHR 3270/4885 |
| US-11230557-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | ALDH1A1 4766/4885SMN1; SMN2 2851/4885TSHR 3270/4885 |
| US-20230331737-A1 | MTORC1 MODULATORS AND USES THEREOF | MTOR, RPTOR, RICTOR | ALDH1A1 4764/4885SMN1; SMN2 1159/4885TSHR 2893/4885 |
| US-20070027318-A1 | Quinoline derivatives and quinazoline derivatives | CYTH3, NQO2, NRAS | ALDH1A1 3029/4885SMN1; SMN2 4179/4885TSHR 2645/4885 |
| US-20210002300-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | ALDH1A1 4766/4885SMN1; SMN2 2851/4885TSHR 3270/4885 |
| US-20230013344-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | ALDH1A1 4766/4885SMN1; SMN2 2851/4885TSHR 3270/4885 |
| US-11021492-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | ALDH1A1 4766/4885SMN1; SMN2 2851/4885TSHR 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.